Last updated: 2026-10-14 00:12:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aligos Therapeutics, Inc. (ALGS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5.55, with a market capitalization of $33.35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.98 to $13.69. This page covers its latest market performance, valuation, price trends and company information.
$33.35M | |
$5.52 | |
$937.75 | |
$3.76 | |
$5.53 | |
33.36K | |
85.23K | |
-- | |
$13.69 | |
$3.98 | |
-- | |
-- |
Aligos Therapeutics, Inc. (ALGS) last closed at $5.53 as of 2026-10-13 23:31:00, unchanged from the previous close of $5.53.
During the latest regular trading session, ALGS traded between $3.76 and $937.75, with a volume of 33.36K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Aligos Therapeutics, Inc. (ALGS) moved from $5.54 to $5.55, representing a gain of 0.18% ($0.01).
The stock traded between $5.08 and $5.72 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 30.51 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.2%
ALGS is currently trading at $5.55, placing it 16.2% of the way from its 52-week low of $3.98 to its 52-week high of $13.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 82 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aligos Therapeutics, Inc. (ALGS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.